GlassScriptPhysician profile
Maghan Ashmore
NPI 1720624430
$1,981.18
in general payments reported to CMS, 2019-2025
22 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $392 · 2022: $210 · 2023: $339 · 2024: $580 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $633.53 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $185.59 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $169.35 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.32 | 2022-2024 | |
| Abbvie INC. | $121.06 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $113.90 | 2021-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $92.91 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.00 | 2021-2025 | |
| Alpha Cognition USA, INC. | $67.69 | 2025 | Zunveyl |
| Glaxosmithkline, LLC. | $61.49 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $59.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $53.58 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.69 | 2022 | |
| Ardelyx, INC. | $27.91 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $26.12 | 2024 | Dificid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $22.07 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.72 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.11 | 2024 | Voquezna |
| Organogenesis INC. | $16.19 | 2023 | Puraply |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2022 | |
| Amgen INC. | $12.80 | 2023 | Repatha |
| Janssen Biotech, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maghan Ashmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.